volume 43 issue 2 pages 517-537

Targeting mitochondrial dysfunction with small molecules in intervertebral disc aging and degeneration

Morteza Saberi 1
Xiaolei Zhang 2, 3
Ali Mobasheri 4, 5, 6, 7
Publication typeJournal Article
Publication date2021-02-26
scimago Q1
wos Q1
SJR1.564
CiteScore8.6
Impact factor5.4
ISSN25092715, 25092723
Geriatrics and Gerontology
Aging
Abstract
The prevalence of rheumatic and musculoskeletal diseases (RMDs) including osteoarthritis (OA) and low back pain (LBP) in aging societies present significant cost burdens to health and social care systems. Intervertebral disc (IVD) degeneration, which is characterized by disc dehydration, anatomical alterations, and extensive changes in extracellular matrix (ECM) composition, is an important contributor to LBP. IVD cell homeostasis can be disrupted by mitochondrial dysfunction. Mitochondria are the main source of energy supply in IVD cells and a major contributor to the production of reactive oxygen species (ROS). Therefore, mitochondria represent a double-edged sword in IVD cells. Mitochondrial dysfunction results in oxidative stress, cell death, and premature cell senescence, which are all implicated in IVD degeneration. Considering the importance of optimal mitochondrial function for the preservation of IVD cell homeostasis, extensive studies have been done in recent years to evaluate the efficacy of small molecules targeting mitochondrial dysfunction. In this article, we review the pathogenesis of mitochondrial dysfunction, aiming to highlight the role of small molecules and a selected number of biological growth factors that regulate mitochondrial function and maintain IVD cell homeostasis. Furthermore, molecules that target mitochondria and their mechanisms of action and potential for IVD regeneration are identified. Finally, we discuss mitophagy as a key mediator of many cellular events and the small molecules regulating its function.
Found 
Found 

Top-30

Journals

1
2
Frontiers in Genetics
2 publications, 3.7%
Frontiers in Pharmacology
2 publications, 3.7%
Frontiers in Immunology
2 publications, 3.7%
Experimental and Molecular Medicine
2 publications, 3.7%
Oxidative Medicine and Cellular Longevity
2 publications, 3.7%
Scientific Reports
2 publications, 3.7%
DNA and Cell Biology
1 publication, 1.85%
Frontiers in Bioengineering and Biotechnology
1 publication, 1.85%
Frontiers in Cardiovascular Medicine
1 publication, 1.85%
Nutrients
1 publication, 1.85%
GeroScience
1 publication, 1.85%
Phytochemistry Reviews
1 publication, 1.85%
Inflammation
1 publication, 1.85%
Phytomedicine
1 publication, 1.85%
Biomedicine and Pharmacotherapy
1 publication, 1.85%
Prague medical report
1 publication, 1.85%
Frontiers in Public Health
1 publication, 1.85%
Functional and Integrative Genomics
1 publication, 1.85%
BMC Medical Genomics
1 publication, 1.85%
Small
1 publication, 1.85%
Frontiers in Molecular Biosciences
1 publication, 1.85%
Arthritis Research and Therapy
1 publication, 1.85%
Redox Biology
1 publication, 1.85%
Pathology and Oncology Research
1 publication, 1.85%
Cell Biology and Toxicology
1 publication, 1.85%
Bioactive Materials
1 publication, 1.85%
Advanced Science
1 publication, 1.85%
Biological Research
1 publication, 1.85%
Osteoarthritis and Cartilage
1 publication, 1.85%
1
2

Publishers

2
4
6
8
10
12
14
16
Elsevier
15 publications, 27.78%
Springer Nature
13 publications, 24.07%
Frontiers Media S.A.
11 publications, 20.37%
MDPI
3 publications, 5.56%
Hindawi Limited
2 publications, 3.7%
Wiley
2 publications, 3.7%
Mary Ann Liebert
1 publication, 1.85%
Universitas Carolina Pragensis
1 publication, 1.85%
Spandidos Publications
1 publication, 1.85%
Taylor & Francis
1 publication, 1.85%
American Chemical Society (ACS)
1 publication, 1.85%
2
4
6
8
10
12
14
16
  • We do not take into account publications without a DOI.
  • Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
54
Share
Cite this
GOST |
Cite this
GOST Copy
Saberi M. et al. Targeting mitochondrial dysfunction with small molecules in intervertebral disc aging and degeneration // GeroScience. 2021. Vol. 43. No. 2. pp. 517-537.
GOST all authors (up to 50) Copy
Saberi M., Zhang X., Mobasheri A. Targeting mitochondrial dysfunction with small molecules in intervertebral disc aging and degeneration // GeroScience. 2021. Vol. 43. No. 2. pp. 517-537.
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.1007/s11357-021-00341-1
UR - https://doi.org/10.1007/s11357-021-00341-1
TI - Targeting mitochondrial dysfunction with small molecules in intervertebral disc aging and degeneration
T2 - GeroScience
AU - Saberi, Morteza
AU - Zhang, Xiaolei
AU - Mobasheri, Ali
PY - 2021
DA - 2021/02/26
PB - Springer Nature
SP - 517-537
IS - 2
VL - 43
PMID - 33634362
SN - 2509-2715
SN - 2509-2723
ER -
BibTex |
Cite this
BibTex (up to 50 authors) Copy
@article{2021_Saberi,
author = {Morteza Saberi and Xiaolei Zhang and Ali Mobasheri},
title = {Targeting mitochondrial dysfunction with small molecules in intervertebral disc aging and degeneration},
journal = {GeroScience},
year = {2021},
volume = {43},
publisher = {Springer Nature},
month = {feb},
url = {https://doi.org/10.1007/s11357-021-00341-1},
number = {2},
pages = {517--537},
doi = {10.1007/s11357-021-00341-1}
}
MLA
Cite this
MLA Copy
Saberi, Morteza, et al. “Targeting mitochondrial dysfunction with small molecules in intervertebral disc aging and degeneration.” GeroScience, vol. 43, no. 2, Feb. 2021, pp. 517-537. https://doi.org/10.1007/s11357-021-00341-1.